clinical trial · NCT06922448
Study of BLU-808 in Allergic Rhinoconjunctivitis
Allergic RhinoconjunctivitisBLU-808Placebo
brief summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (ARC). Participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (AEC).
started
Apr 14, 2025
primary completion
Sep 8, 2025
completion
Sep 8, 2025
last updated
Feb 10, 2026
official title
A Phase 2a Randomized Double-blinded Placebo Controlled Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Clinical Activity of BLU-808, a Wild-type KIT Inhibitor, in Participants With Ragweed (Ambrosia Artemisiifolia)-Induced Allergic Rhinoconjunctivitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol